2009.03 12 Weekly Broadcast Email
The following updates were made the website for the week of March 9, 2009.
Study Accrual Goal Reached!
97202 (A Randomized Double-Blind Placebo-Controlled Study of Oral Coenzyme Q10 to Relieve Self-Reported Cancer Treatment Related Fatigue in Breast Cancer Patients)
The 97202 accrual goal of 236 patients was achieved on 3/9/08. The study is closed to accrual and an official closure letter will we released once approved by the WFU IRB. Congratulations to all the Research Base sites who participated in 97202!
91105 (Phase III Double Blind, Placebo Controlled Study of Donepezil in Irradiated Brain Tumor Patients)
Amendment 6 has been approved and posted to the website. This amendment includes consent changes as well as revisions to Appendices 2, 12, 13, 14, and the addition of 16. The Help Tool document on the appendices page has also been amended.
97405 (Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men with Prostate Cancer)
Since the closure of the COLD-fX, is your site looking for a new study? Then consider enrolling patients in the Soy/Effexor trial.
Thank you to those sites who participated in the conference call on Monday. We appreciated hearing your ideas and feedback. Please contact the PIO if you have any further questions regarding the study.
Our goal is to have 125 more patients registered by June 1st. Click here to download the protocol documents, view slide show presentations, and more. Consider joining the Research Base in reaching its June 1st goal!
There is a short survey attached to this message regarding a Research Base study in development. Please complete this survey and return to firstname.lastname@example.org with five (5) working days.
The CCCWFU Research Base is sponsoring a one day intensive training workshop for sites that intend to participate in study # 91105 " A Phase III Double Blind, Placebo Controlled Study of Donepezil in Irradiated Brain Tumor Patients" which is testing a well-tolerated drug used to enhance cognitive performance in brain tumor patients who are >6 months post brain radiation therapy and who meet other study criteria. This one day intensive session will be held on March 25, 2009 on the campus of Wake Forest University Baptist Medical Center in Winston-Salem, NC. There are no fees associated with registration for this session. If you need further information about this training session, please contact Lisa Hawkins at email@example.com.